Crescent Capital Consulting’s Exelixis EXEL Stock Holding History

Crescent Capital Consulting’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-67	Closed	-$1K	–	588
2021 Q2	$1K	Buy	+67	New	+$1.56K	﹤0.01%	474

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crescent Capital Consulting's EXEL Position: Q3 2021 in Review

Crescent Capital Consulting sold out of Exelixis (EXEL) in Q3 2021, closing a stake of 67 shares — an estimated $1K sold.

Crescent Capital Consulting first reported a position in EXEL in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 339 funds tracked by Wall St. Rank hold EXEL as of Q3 2021.

Crescent Capital Consulting reported no remaining Exelixis position as of Q3 2021 after selling out during the quarter.
Crescent Capital Consulting sold 67 Exelixis shares in Q3 2021, an estimated $1K.
Crescent Capital Consulting first reported a position in Exelixis in Q2 2021 and held it in 1 quarter.
Crescent Capital Consulting's Exelixis position peaked at $1K in Q2 2021.
339 funds tracked by Wall St. Rank held Exelixis as of Q3 2021.

Based on Crescent Capital Consulting's 13F filing for Q3 2021, filed 12 Oct 2021.